Source: United Kingdom – Executive Government & Departments
Scientists comment on NICE final draft guidance and the NHS rollout of Alyftrek for Cystic Fibrosis.
David Ramsden, Cystic Fibrosis Trust Chief Executive, said:
“Today’s announcements are a positive step in the journey to better treatments for more people with cystic fibrosis – a lifelong, life-limiting condition without a cure. It’s thanks to the incredible hard work and support of the CF community and everyone we work with that modulator drugs are now a treatment option for many, but not all people with CF.
“Cystic fibrosis continues to make lives too tough and too short, which is why we will continue funding vital research to work towards a future where everyone can benefit from a life unlimited by CF.”
Prof Kevin Southern, Professor of Child Health, Chair, UK CF Medical Association, said:
“The CFMA welcome the approval of Alyfrek, which may offer an important alternative for some people with CF who are already treated with Kaftrio, or be an option for a small number of people who are not eligible for current therapies or have not been able to tolerate them. CF remains a condition without a cure and while improvements to therapies is good news, ongoing challenges exist for people with the condition. CF clinical teams will continue to work to achieve excellent health outcomes and quality of life for all, and we hope that in the future, new therapies will become available for people with CF, particularly for those who do not respond to existing therapies.”
The NICE final draft guidance on Alyftrek was published on the NICE website at 00:01 UK time on Tuesday 15 July.
https://www.nice.org.uk/guidance/indevelopment/gid-ta11430/documents
Declared interests
No reply to our request for DOIs was received.